MedTrace Logo

Gaze-Contingent Music Reward Treatment for PTSD

NCT05057624 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2025-02-13

No results posted yet for this study

Summary

The present study is a double-blind trial that seeks to examine the feasibility, acceptability, and efficacy of a recently developed eye-tracking-based, gaze-contingent music reward therapy (GC-MRT) in individuals with posttraumatic stress disorder (PTSD).

The specific aims of this study are to: (1) examine the efficacy of GC-MRT in PTSD; and (2) elucidate its underpinnings (i.e. attention control, reward processes, and exposure via counter-conditioning).

The investigators hypothesize that:

1. GC-MRT will produce greater reductions in symptoms compared to PC at post-treatment and follow-up (diverting attention away from threat).
2. GC-MRT-exp will produce greater reductions in symptoms compared to PC at post-treatment follow-up (exposure via counter-conditioning by rewarding threat stimuli).
3. Exploratory analysis will compare the reductions in symptoms of GC-MRT compared to GC-MRT-exp at post-treatment follow-up.

Conditions

Interventions

OTHER

Exposure

Participants will hear music of their choice when they focus on angry faces, and when they look at neutral faces the music will stop.

OTHER

Placebo GC-MRT

Participants will hear music continuously throughout the trials, without regard to the faces they look at.

OTHER

GC-MRT

Participants will hear music as a reward for looking at neutral faces and the music will stop when they focus on angry faces.

Sponsors & Collaborators

  • Research Foundation for Mental Hygiene, Inc.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2024-09-14
Completion
2025-03-14

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05057624 on ClinicalTrials.gov